Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 4/20 | 0.65 |
| ▸ | CRBN | Q96SW2 | 9/20 | 0.58 |
| ▸ | MAP1LC3B | Q9GZQ8 | 5/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.58 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.58 |
| ▸ | TNF | P01375 | 2/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.58 |
| ▸ | IL1B | P01584 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30438189 | 1.00 | STAT3 (0.65) | STAT3CRBNMAP1LC3BIKZF3DDB1 | |
| SCHEMBL20913625 | 1.00 | STAT3 (0.65) | STAT3CRBNMAP1LC3BIKZF3DDB1 | |
| SCHEMBL30376389 | 1.00 | STAT3 (0.65) | STAT3CRBNMAP1LC3BIKZF3DDB1 | |
| SCHEMBL19451343 | 1.00 | STAT3 (0.65) | STAT3CRBNMAP1LC3BIKZF3DDB1 | |
| SCHEMBL19451341 | 1.00 | STAT3 (0.65) | STAT3CRBNMAP1LC3BIKZF3DDB1 | |
| SCHEMBL30241717 | 1.00 | STAT3 (0.65) | STAT3CRBNMAP1LC3BIKZF3DDB1 | |
| SCHEMBL19451342 | 0.99 | STAT3 (0.63) | STAT3CRBNMAP1LC3BIKZF3DDB1 | |
| SCHEMBL30437927 | 0.99 | STAT3 (0.63) | STAT3CRBNMAP1LC3BIKZF3DDB1 | |
| SCHEMBL26815429 | 0.97 | STAT3 (0.61) | STAT3CRBNMAP1LC3BIKZF3DDB1 | |
| SCHEMBL19451359 | 0.95 | STAT3 (0.64) | STAT3CRBNMAP1LC3BIKZF3DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110615779-B | Process for preparing lenalidomide derivatives | 上海科技大学 | 2023-03-24 | — | — | CN | claimed |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | claimed |
| CN-110615779-A | Process for preparing lenalidomide derivatives | 上海科技大学 | 2019-12-27 | — | — | CN | claimed |
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent KGaA (DE) | 2025-01-30 | — | — | US | disclosed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | disclosed |
| US-20220411432-A1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-12-29 | — | — | US | disclosed |
| WO-2021262693-A1 | METHOTREXATE ANALOGS AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-12-30 | — | — | WO | disclosed |
| US-11192898-B2 | MDM2 protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | disclosed |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2021-01-07 | — | — | US | disclosed |
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-09-01 | — | — | US | disclosed |
| US-10633386-B2 | BET protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-04-28 | — | — | US | disclosed |
| US-20190169195-A1 | BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-06-06 | — | — | US | disclosed |
| US-20190127387-A1 | MDM2 PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2019-04-25 | — | — | US | disclosed |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | UNIV MICHIGAN REGENTS (US) | 2019-04-25 | — | — | US | disclosed |
| WO-2017180417-A1 | BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017176957-A1 | MDM2 PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192898-B2 | MDM2 protein degraders | MDM2, TP53, TP53BP1 | STAT3 1275/4885CRBN 605/4885MAP1LC3B 1372/4885 |
| US-20190119289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | STAT3 719/4885CRBN 151/4885MAP1LC3B 1358/4885 |
| US-10759808-B2 | Monofunctional intermediates for ligand-dependent target protein degradation | MDM2, CD74, TNFSF10 | STAT3 719/4885CRBN 151/4885MAP1LC3B 1358/4885 |
| US-20220411432-A1 | MDM2 PROTEIN DEGRADERS | MDM2, TP53, TP53BP1 | STAT3 1275/4885CRBN 605/4885MAP1LC3B 1372/4885 |
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, UBQLN1, TTI1 | STAT3 3368/4885CRBN 2656/4885MAP1LC3B 278/4885 |
| US-20210002289-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | MDM2, CD74, TNFSF10 | STAT3 719/4885CRBN 151/4885MAP1LC3B 1358/4885 |
| US-10633386-B2 | BET protein degraders | BRD4, BET1, BRD1 | STAT3 482/4885CRBN 203/4885MAP1LC3B 1330/4885 |
| US-20190169195-A1 | BET PROTEIN DEGRADERS | BRD4, BET1, BRD1 | STAT3 484/4885CRBN 195/4885MAP1LC3B 1362/4885 |
| US-20190127387-A1 | MDM2 PROTEIN DEGRADERS | MDM2, TP53, TP53BP1 | STAT3 1275/4885CRBN 605/4885MAP1LC3B 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.